BUY Mankind Pharma Limited — Nirmal Bang Securities
byNirmal Bang SecuritiesHorizon: NA (inferred 1 year)27 Oct 2026via ET Now (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
NewsEt-Markets·27 Oct · today
Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%
NewsNdtv-Profit·27 Oct · today
Mankind Pharma Q2 profit rises 38% to Rs 716 crore
NewsEt-Markets·27 Oct · today
5 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days
Advisor consensus · same horizon·27 Oct · today
Mankind Pharma Q2 profit jumps 39% to ₹712 crore as revenue rises 17%
NewsCnbc-Tv18·26 Oct · yesterday
Mankind Pharma Q2 Review: Export Momentum Continues; Systematix Maintains 'Hold'; Check Target Price
NewsNdtv-Profit·27 Oct · today
Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
NSE · Outcome of Board Meeting·26 Oct · yesterday
Mankind Pharma To Give Rs 1 Crore To Flydubai Captain Smit Machchhar, Family For Averting Flight Disaster
NewsNdtv-Profit·3 Oct · 3w ago
Mankind Pharma auditor resigns as subsidiary Bharat Serums enters liquidation
NewsGoogle News·28 Sept · 4w ago
Mankind Pharma's subsidiary Bharat Serums and Vaccines sees auditor resignation amid liquidation
NewsGoogle News·28 Sept · 4w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock
Advisor consensus · same horizon·31 Jul · 3mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Mankind Pharma
- BUY — Vaishali Parekh, Prabhudas Lilladher27 Oct 2026 · Same day · target ₹2,500 · Expired
- BUY — Rakesh Bansal27 Oct 2026 · Same day · target ₹2,520 · Target hit
- BUY — Kotak Securities27 Oct 2026 · ~1 year · target ₹3,035 · Active
- BUY — Jefferies India27 Oct 2026 · ~1 year · target ₹2,900 · Active
- BUY — Rakesh Bansal26 Oct 2026 · ~2 weeks · target ₹2,330 · Expired
More from Nirmal Bang Securities
- BUY Swiggy23 Oct 2026 · ~1 year · target ₹340 · Active
- BUY Rossari Biotech21 Oct 2026 · ~1 year · target ₹680 · Active
- SELL HCL Technologies13 Oct 2026 · ~1 year · target ₹1,014 · Active
- BUY Sterlite Technologies5 Oct 2026 · ~1 year · target ₹1,340 · Active
- BUY WeWork India Management30 Sept 2026 · ~1 year · target ₹983 · Active

